All listings for this product
Best Selling in Non-Fiction Books
- AU $60.15New
- AU $21.21New
- AU $24.85New
- AU $19.97New
Allen Carr's Easy Way to Stop Smoking: Be a Happy Non-smoker for the Rest of Your Life by Allen Carr (Paperback, 2013)
- AU $24.81New
- AU $11.56Used
Cravings: Recipes for All the Food You Want to Eat by Adeena Sussman, Chrissy Teigen (Hardback, 2016)
- AU $43.52New
- AU $32.03New
Save on Non-Fiction Books
- AU $18.96Trending at AU $21.21
- AU $22.97Trending at AU $26.99
- AU $18.58Trending at AU $23.86
- AU $62.84Trending at AU $78.06
- AU $16.85Trending at AU $18.80
- AU $79.14Trending at AU $90.48
- AU $40.94Trending at AU $50.32
About this product
- DescriptionThe purpose of this publication is to introduce a new, simpler and more effective way in which to interpret pharmaceutical aerosol particle size data from orally inhaled products (OIPs). Currently, the compendial and regulatory requirements dictate the need for measurements by full resolution multi-stage cascade impactor (CI), a process that is demanding for the operator, time consuming, prone to experimental error, and challenging for method transfers from one laboratory to ather. Furthermore, we shall show that the current practice of reducing information from mass-weighted aerodynamic particle size distribution (APSD) measurements through the use of CI stage groupings is t the most effective decision-making tool for OIP quality control (QC) in comparison with newly introduced, mutually-independent efficient data analysis (EDA) metrics that can be derived either from full resolution or abbreviated impactor measurements (AIM).
- Author BiographyTerrence P. Tougas, Ph.D. Terrence Tougas, Ph.D. is a Highly Distinguished Research Fellow in Analytical Development at Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT where he has over 20 years of experience and currently heads the Stability, Submission Documents and Information Systems Group. He contributed to chemistry, manufacturing and controls sections of several New Drug Applications, including for pulmonary (metered dose inhalers, inhalation solutions and nasal sprays) and antiviral products. Dr. Tougas is a member and past chair of the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) Board of Directors, and has been leader or member of several IPAC-RS working groups. Dr. Tougas served on the Steering Committee and chaired the Drug Product Technical Committee of the Product Quality Research Institute (PQRI). More recently, he helped form the International Consortium on Innovation and Quality in Pharmaceutical Development (IQ), served as the first chair of its Board of Directors and is a member of the IQ Statistics Leadership Group. Dr. Tougas authored numerous publications related to the CMC aspects of drug development, analytical chemistry and quality control statistics. He contributed chapters to books on chromatography and leachables/extractables testing of inhalation products. His background is in analytical chemistry; he holds a Ph.D in chemistry from the University of Massachusetts, Amherst. Jolyon P. Mitchell, Ph.D. Jolyon Mitchell, Ph.D. is Scientific Director at Trudell Medical International, London, Canada. He is involved in several industry-wide organizations involved with inhaled medical aerosol delivery, in particular the European Pharmaceutical Aerosol Group (EPAG) as well as serving as a Scientific Adviser to IPAC-RS. He played major parts in the development of an international standard (ISO 20072:2009) covering the design verification of portable inhalers, as well as a Canadian Standard for Spacers and Holding Chambers (CAN/CSA Z264.1-02:2002). He is currently a Canadian delegate to ISO/TC121/SC2, involved with the ongoing development of a standard specifically for nebulizing systems (ISO 27427). In 2010, he was recently appointed to the Expert Committee: General Chapters - Dosage Forms of the United States Phamacopeial Convention for the 2010-2015 term, where he serves as vice chair of the Aerosols dosage form sub-committee. His background is in physical chemistry. He is a Fellow of the UK Royal Society of Chemistry, a Chartered Scientist, a founder member of the UK-Irish Aerosol Society and a member of the Gesellschaft fur Aerosolforschung, American Association for Aerosol Research, American Association of Pharmaceutical Scientists and the International Society for Aerosols in Medicine. He is on the Editorial Advisory Board of Journal of Aerosol Medicine. He is also an adjunct professor at the University of Western Ontario. Svetlana A. Lyapustina, Ph.D. Svetlana Lyapustina, Ph.D. is a Senior Science Advisor in the Pharmaceutical Practice Group of the Washington, D.C. office of Drinker Biddle & Reath LLP. As a member of that multi-disciplinary team, Dr. Lyapustina has served as Science Advisor and Secretariat for several industry consortia, including the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS), the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ), an International Pharmaceutical Supply Chain Consortium Rx-360, Alliance for Biosecurity, Nanomedicines Alliance, and Allotrope Foundation. She was an active member of the Product Quality Research Institute (PQRI), of a Project Team of the United States Pharmacopeia, and a US National Expert in the International Organization for Standardization (ISO). Dr. Lyapustina counsels clients on a wide range of topics related to drug and device product development, pharmaceutical manufacturing, regulatory compliance, quality control, bioe
- PublisherSpringer-Verlag New York Inc.
- Date of Publication10/04/2013
- SubjectMedicine: General
- Place of PublicationNew York, NY
- Country of PublicationUnited States
- ImprintSpringer-Verlag New York Inc.
- Content Note70 black & white tables, biography
- Weight841 g
- Width155 mm
- Height235 mm
- Spine28 mm
- Edited byJolyon P. Mitchell,Svetlana A. Lyapustina,Terrence P. Tougas
This item doesn't belong on this page.
Thanks, we'll look into this.